Future directions in thrombolysis
Corresponding Author
James T. Willerson M.D.
Department of Medicine, University of Texas Medical School at Houston, and the Memorial-Hermann Hospital, and Texas Heart Institute in Houston, Texas, USA
Department of Medicine P.O. Box 20708 University of Texas Medical School at Houston Houston, TX 77225, USASearch for more papers by this authorPierre Zoldhelyi M.D.
Department of Medicine, University of Texas Medical School at Houston, and the Memorial-Hermann Hospital, and Texas Heart Institute in Houston, Texas, USA
Search for more papers by this authorCorresponding Author
James T. Willerson M.D.
Department of Medicine, University of Texas Medical School at Houston, and the Memorial-Hermann Hospital, and Texas Heart Institute in Houston, Texas, USA
Department of Medicine P.O. Box 20708 University of Texas Medical School at Houston Houston, TX 77225, USASearch for more papers by this authorPierre Zoldhelyi M.D.
Department of Medicine, University of Texas Medical School at Houston, and the Memorial-Hermann Hospital, and Texas Heart Institute in Houston, Texas, USA
Search for more papers by this authorAbstract
An extensive body of research conducted in the past 25 years has helped foster understanding of the mechanisms and pathogenesis of the acute coronary syndromes and occlusive disease. Thus, it is well established that thrombosis is caused by vascular injury and that immediate lysis of the arterial thrombus and subsequent prevention of thrombotic reocclusion are critical to the treatment of these disorders. Remarkable progress in the understanding of the biological and molecular mechanisms involved in vascular-wall-platelet interactions, platelet-platelet interactions, and coagulation has led to the identification of multiple targets for drug discovery and the development of numerous antithrombotic drugs. The purpose of this article is to review emerging antithrombotic therapies, introduce potential future molecular targets for drug discovery efforts, and discuss novel strategies for managing patients with coronary disease.
References
- 1 Andrews TC, Mudge GH Jr: Coronary artery disease. In Vascular Medicine (Eds. J Loscalzo, MA Creager, VJ Dzau), p. 799–833. Boston, Mass: Little, Brown and Co., 1992
- 2 Davies MJ, Bland JM, Hangartner JRW, Angelini A, Thomas AC: Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989; 10: 203–208
- 3 Davies MJ, Thomas A: Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137–1140
- 4 Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242–250
- 5 Hawiger J: Platelets in thrombosis and rethrombosis. In Molecular Cardiovascular Medicine (Ed. E Haber), p. 157–175. New York: Scientific American, Inc., 1995
- 6 Rosenberg RD, Aird WC: Thrombosis. In Molecular Cardiovascular Medicine (Ed. E Haber), p. 115–132. New York: Scientific American, Inc., 1995
- 7 Davies MJ: The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res 1996; 82 (1):1–32
- 8 Fuster V, Fallon JT, Nemerson Y: Coronary thrombosis. Lancet 1996; 348: s7–s10
- 9 Gimbrone MA Jr: Vascular endothelium in health and disease. In Molecular Cardiovascular Medicine (Ed. E Haber), p. 49–61. New York: Scientific American, Inc., 1995
- 10 Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–2850
- 11 Stormorken H, Sakariassen KS: Hemostatic risk factors in arterial thrombosis and atherosclerosis: The thrombin-fibrin and platelet-vWF axis. Thromb Res 1997; 88: 1–25
- 12 Haines ST, Bussey HJ: Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 1995; 29: 892–904
- 13 Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT: Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685–691
- 14 Willerson JT, Campbell WB, Winniford MD, Schmitz J, Apprill P, Firth B, Ashton J, Smitherson T, Bush L, Buje LM: Conversion from chronic to acute coronary artery disease: Speculation regarding mechanisms. Am J Cardiol 1984; 54: 1349–1357
- 15 Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM: Specific platelet mediators and unstable coronary artery lesions: Experimental evidence and potential clinical implications. Circulation 1989; 80: 198–205
- 16 Wu KK: Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med 1996; 239: 17–34
- 17 Messmore HL Jr, Wehrmacher WH, Coyne E: The clinical utility of antiplatelet drugs. Cardiovasc Rev Rep 1998; XIX: 21–32
- 18 Treatment of Heart Diseases (Eds. JT Willerson, DS Baim, DA Cooley, OH Frazier, SM Grundy, NM Kaplan, M Packer, MS Sweeney, DP Zipec) p. 1.38–1.60. New York: Gower, 1992
- 19 Chesebro JH, Webster MWI, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ: Antithrombotic therapy and progression of coronary artery disease: Antiplatelet vs. antithrombins. Circulation 1992; 86 (suppl III): III-100–III–III
- 20 Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800–806
- 21 Schussheim AE, Fuster V: Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. Prog Cardiovasc Dis 1997; 40: 205–238
- 22 Schafer AI: Coagulation cascade: An overview. In Thrombosis and Hemorrhage (Eds. J Loscalzo, AI Schafer), p. 3–12. Boston, Mass: Blackwell Scientific, 1994
- 23 Muller JE, Kaufmann PG, Luepker RV, Weisfeldt ML, Deedwania PC, Willerson JT: Mechanisms precipitating acute cardiac events: Review and recommendations of an NHLBI workshop. Circulation 1997; 96: 3233–3239
- 24 Ambrose JA, Weinrauch M: Thrombosis in ischemic heart disease. Arch Intern Med 1996; 156: 1382–1394
- 25 Falk E: Why do plaques rupture? Circulation 1992; 86 (suppl III): III–30–III–42
- 26 Fuster V: Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol 1995; 76: 24C–33C
- 27 Johnson JL, Jackson CL, Angelini GD, George SJ: Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1998; 18: 1707–1715
- 28 Yun DD, Alpert JS: Acute coronary syndromes. Cardiology 1997; 88: 223–237
- 29 Kockx MM: Apoptosis in the atherosclerotic plaque: Quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol 1998; 18: 1519–1522
- 30 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979
- 31 Willerson JT: Conversion from chronic to acute coronary heart disease syndromes: Role of platelets and platelet products. Tex Heart Inst J 1995; 22: 13–19
- 32
Coller BS:
Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy.
Circulation
1995;
92:
2372–2380
10.1161/01.CIR.92.9.2373 Google Scholar
- 33 Dobesh PP, Lathem KA: Advancing the battle against acute ischemic syndromes: A focus on the GPIIb/IIIa inhibitors. Pharmacother 1998; 18: 663–685
- 34 Harker LA, Hanson SR, Kelly AB: Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995; 74: 464–472
- 35 Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553–1559
- 36 Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 1994; 3: 1287–1294
- 37 Topol EJ: Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence. Circulation 1998; 97: 211–218
- 38 Verstraete M, Zoldhelyi P: Novel antithrombotic drugs in development. Drugs 1995; 49: 856–884
- 39 Nichols AJ, Ruffolo RR Jr, Huffman WF, Poste G, Samanen J: Development of GP IIb/IIIa antagonists and antithrombotic agents. Trends Pharmacol Sci 1992; 13: 413–417
- 40 Fitzgerald LA, Steiner B, Rall SC Jr, Lo SS, Phillips DR: Protein sequence of endothelial glycoprotein Illa derived from a cDNA clone. J Biol Chem 1987; 262: 3936–3939
- 41 Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E: Platelet membrane glycoprotein GPIIb/IIIa: Member of a family of Arg-Gly-Asp specific adhesion receptors. Science 1986; 231: 1559–1562
- 42 Adgey AAJ: An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998; 135 (suppl 4): S43–S55
- 43 The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–961
- 44 Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M: Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994; 343: 881–886
- 45 Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM: Long-term protection from myocardial ischemic events in a randomized trial of brief integrin b̃3 blockade with percutaneous coronary intervention. J Am Med Assoc 1997; 278: 479–484
- 46 The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696
- 47 The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429–1435
- 48 The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87–92
- 49 The RESTORE Investigators: Effects of platelet glycoprotein IIb/ IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–1453
- 50 The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–443
- 51 The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498–1505
- 52 The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497
- 53 Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian Lamifiban Study. Circulation 1996; 94: 899–905
- 54 The PARAGON Investigators: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina Circulation 1998; 97: 2386–2395
- 55 Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud ARX, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ: Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial. Circulation 1998; 98: 1268–1278
- 56 Quinn M, Fitzgerald DJ: Long-term administration of glycoprotein IIb/IIIa antagonists. Am Heart J 1998; 135: S113–S118
- 57 McGhie AI, McNatt J, Ezov N, Cui K, Mower LK, Hagay Y, Buja M, Garfinkel LI, Gorecki M, Willerson JT: Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand-glycoprotein lb binding domain. Circulation 1994; 90: 2976–2981
- 58 Yao S-K, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, Anderson HV, Panet A, Gorecki M, Buja LM, Willerson JT: Blockade of platelet membrane glycoprotein lb receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation 1994; 89: 2822–2828
- 59 Golino P, Ambrosio G, Ragni M, Cirillo P, Esposito N, Willerson JT, Rothlein R, Petrucci L, Condorelli M, Chiareillo M, Buja LM: Inhibition of leukocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury. Thromb Haemost 1997; 77: 783–788
- 60 Mills DCB, Puri R, Hu CJ, Minniti C, Grana C, Freedman MD, Colman RF, Colman RW: Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430–436
- 61 Sharis PJ, Cannon CP, Loscalzo J: The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394–405
- 62 Dembinska Kiec A, Virgoloni I, Rauscha F, Sinzinger H: Ticlopidine and platelet function in healthy volunteers. Thromb Res 1992; 65: 559–570
- 63 Hass WK, Eaton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–507
- 64 Yao S-K, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand J-P, Campbell WB, Buja LM, Willerson JT: ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992; 70: 39–48
- 65 Yao S-K, Ober JC, Ferguson JJ, Maffrand J-P, Anderson HV, Buja LM, Willerson JT: Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267 (36): H488–H493
- 66 Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–1220
- 67 CAPRIE Steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329–1339
- 68 Stringer KA, Lindenfeld J: Hirudins: Antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535–1540
- 69 White HD, Aylward BM, Frey MJ, Adgey AAJ, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B: Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997; 96: 2155–2161
- 70 Markwardt F: The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1–23
- 71 Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave JP, Courtney M, Tolstoshev P, Lecocq J-P: Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci USA 1986; 83: 1084–1088
- 72 Markwardt F: The comeback of hirudin as an antithrombotic agent. Semin Thromb Haemost 1991; 17: 79–82
- 73 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775–782
- 74 Antman EM: Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94: 911–921
- 75 Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators: Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial infarction without ST elevation: A pilot study. Circulation 1997; 96: 769–777
- 76 Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Bos AA, Umans VA, Fox KA: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757–763
- 77 Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B: Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764–769
- 78 Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, deBono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622–1629
- 79 Lidón RM, Théroux P, Lespérance J, Adelman B, Bonan R, Duval D, Lévesque J: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994; 89: 1567–1572
- 80 Collins CE, Rampton DS: Platelets in inflammatory bowel disease—pathogenic role and therapeutic implications. Aliment Pharmacol Ther 1997; 11: 237–247
- 81 Donnelly MT, Hawkey CJ: Review article: COX-II inhibitors—a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997; 11: 227–236
- 82 Masferrer JL, Isakson PC, Siebert K: Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin N A 1996; 25: 363–372
- 83 Mitchell JA, Evans TW: Cyclooxygenase-2 as a therapeutic target. Inflamm Res 1998; 47 (suppl 2): S88–S92
- 84 Fujise K, Revelle BM, Stacy L, Madison EL, Yeh ETH, Willerson JT, Beck PJ: A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent. Circulation 1997; 95: 715–722
- 85 Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu Y-M, Sajer SA, Furie B: Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848–851
- 86 Zoldhelyi P, Beck PJ, Akhtar S, Ober JC, Bjencke R, Ahmed M, McNatt J, Clubb FC, Yeh ETH, Willerson JT: Prevention of coronary thrombosis after arterial injury by selectin inhibition. 1999 (submitted)
- 87 Zoldhelyi P, McNatt J, Xu X-M, Loose-Mitchell D, Meidell RS, Clubb FJ, Buja LM, Willerson JT, Wu KK: Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation 1996; 93: 10–17
- 88 Zoldhelyi P, McNatt J, Ober JC, Shelat HS, Dillard PM, Wun T-C, Willerson JT: Gene transfer of human tissue factor inhibitor in vitro and to severely atherosclerotic arteries in vivo. 1999 (submitted)